D. Brunner

Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial

Mona Boaz, Shmuel Smetana, Talia Weinstein et al. · The Lancet · 2000 · 1K citations

Urology, Renal Disease, Renal Function +11

Rationale and design of a secondary prevention trial of increasing serum high-density lipoprotein cholesterol and reducing triglycerides in patients with clinically manifest atherosclerotic heart disease (the bezafibrate infarction prevention trial)

Uri Goldbourt, Solomon Behar, Henrietta Reicher-Reiss et al. · The American Journal of Cardiology · 1993 · 157 citations

Metabolic Syndrome, Secondary Prevention Trial, Cardiovascular Disease +8

Relation of serum total cholesterol and high-density lipoprotein cholesterol percentage to the incidence of definite coronary events: Twenty-year follow-up of the donolo-Tel Aviv prospective coronary artery disease study

D. Brunner, Joshua Weisbort, Nissim Meshulam et al. · The American Journal of Cardiology · 1987 · 155 citations

Serum Total Cholesterol, Cardiovascular Epidemiology, Cardiovascular Disease +10

Elevated Serum Triglyceride Levels and Long-Term Mortality in Patients With Coronary Heart Disease

Moti Haim, Michal Benderly, D. Brunner et al. · Circulation · 1999 · 142 citations

Fibrinogen Is a Predictor of Mortality in Coronary Heart Disease Patients

Michal Benderly, E. Graff, Henrietta Reicher-Reiss et al. · Arteriosclerosis Thrombosis and Vascular Biology · 1996 · 119 citations · Full text

Thrombosis, Fibrinogen Levels, Plasma Fibrinogen Level +15